Litrature review of human papillomavirus vaccine acceptability among women over 26 years

Department of Pediatrics, University of Texas Medical Branch, 301 University Boulevard, Galveston, TX 77555-0319, United States.
Vaccine (Impact Factor: 3.62). 03/2009; 27(11):1668-73. DOI: 10.1016/j.vaccine.2009.01.035
Source: PubMed


Vaccines for the human papillomavirus (HPV) are currently licensed for females, ages 9 through 26 years old in the U.S., and for adult women up to 45 years in some countries such as Australia. As licensure for adult women, over 26 years, is sought in other countries, it will be important to determine the acceptability to them. We reviewed the available articles on adult opinions and acceptability of vaccinating women against HPV. Predictors of acceptability included barriers, knowledge, risk, age, and marital status. Overall, acceptability rates were high, if adequate information was given and the cost was affordable.

Download full-text


Available from: Lora L. Black, May 13, 2015
49 Reads
  • Source
    • "In a recent literature review of studies exploring factors affecting HPV vaccine acceptance among adult women considering vaccination for themselves, Black et al. observed that the extent of knowledge of HPV infection and its connection to cervical cancer, the perception of risk for HPV infection or cervical cancer, the cost of the vaccine, and misinformation about HPV vaccine were all factors associated with vaccine acceptability for adult women [9]. Although the individual studies differ in methodology and focus, the main conclusion was that women generally were receptive toward HPV vaccine. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The GAVI Alliance's decision in late 2011 to invite developing countries to apply for funding for human papillomavirus (HPV) vaccine introduction underscores the importance of understanding levels of HPV vaccine acceptance in developing country settings. In this paper, we present findings from qualitative research on parents' rationales for vaccinating or not vaccinating their daughters (vaccine acceptance) and their decision-making process in the context of an HPV vaccination demonstration project in Vietnam (2008-2009). We designed a descriptive qualitative study of HPV vaccine acceptability among parents of girls eligible for vaccination in four districts of two provinces in Vietnama. The study was implemented after each of two years of vaccinations was completed. In total, 133 parents participated in 16 focus group discussions and 27 semi-structured interviews. Focus group discussions and in-depth interviews with parents of girls vaccinated revealed that they were generally very supportive of immunization for disease prevention and of vaccinating girls against HPV. The involvement of the National Expanded Program of Immunization in the demonstration project lent credibility to the HPV vaccine, contributing to high levels of acceptance. For parents who declined participation, concerns about side effects, the possibility that the vaccine was experimental, and the possible impact of the vaccine on future fertility rose to the surface. In terms of the decision-making process, many parents exhibited 'active decision-making,' reaching out to friends, family, and opinion leaders for guidance prior to making their decision. Vietnam's HPV vaccination experience speaks to the importance of close collaboration with the government to make the most of high levels of trust, and to reduce suspicions about new vaccines that may arise in the context of vaccine introduction in developing country settings.
    BMC Public Health 08/2012; 12(1):629. DOI:10.1186/1471-2458-12-629 · 2.26 Impact Factor
  • Source
    • "The US Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination of girls aged 11-12 and catch-up vaccination of females aged 13–26 with either vaccine [7]. Both vaccines have been studied in women over 26 [8] [9] and are approved or under regulatory review in several countries for use in older women [10]. HPV vaccine acceptability is generally high in women over 26 [11] [12] but a number of studies report a decrease in vaccine acceptability with increasing age [13] [14] [15] [16] [17] [18], which raises the questions of whether and why older women think the vaccine is relevant to them. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The purpose of this study was to identify attitudes toward HPV vaccination among US women 27 to 45 years of age. A survey was mailed to 2,750 insured US women to assess perceptions of relevance or irrelevance of the HPV vaccine, the underlying reasons, and, for those reporting relevance, the likelihood of vaccination if it became available. Among the 451 eligible respondents, 304 (67.4%) reported that the HPV vaccine was relevant to them, whereas 143 (31.7%) stated that it was not at all relevant. The most common reasons for relevance were protection from cervical cancer (62.8%), vaginal cancer (58.2%), precancerous cells (55.9%), HPV (55.6%), and genital warts (46.4%). Reasons for irrelevance were most commonly being married (54.0%) or in a monogamous relationship (39.6%). Most respondents reporting relevance of the HPV vaccine were likely (33.4%) or extremely likely (37.7%) to receive the vaccine if approved for their age group.
    ISRN obstetrics and gynecology 04/2011; 2011(2090-4436):670318. DOI:10.5402/2011/670318
  • Source
    • "Barriers to vaccination in young women ages 9–26 years include not being sexually active, concern about vaccine safety, and cost [17]. Barriers to vaccination in adult women include cost, limited knowledge about HPV, and perception of a low risk for HPV infection or cervical cancer [13]. There is no published data to date examining qHPV vaccination rates in men. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Prior to FDA licensure in men, a surgical practice (SG) offered the quadrivalent HPV vaccine (qHPV) off-label to men who have sex with men (MSM). We administered a written or telephone survey to MSM to elicit drivers and barriers to vaccination, sexual behavior changes post-vaccination, and knowledge. 191 subjects enrolled: 68 refused qHPV, 71 received qHPV <1 year ago, and 52 received qHPV >1 year ago. History of HPV infection (86%, n=164) and level of HPV and qHPV knowledge were high, with a mean of 10.8 of 13 knowledge questions correct. Ninety-seven percent of participants understood that qHPV does not cure present infection or disease. MSM refused qHPV for reasons including cost and not FDA approved; prevention of future HPV infection was the paramount driver for immunization. Vaccination did not affect sexual behavior.
    Vaccine 10/2010; 29(3):570-6. DOI:10.1016/j.vaccine.2010.09.101 · 3.62 Impact Factor
Show more